| Paris | |
| 113 | |
| Onxeo is a leading developer of orphan oncology drugs. Onxeos vision is to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, by developing advanced, effective and safe therapeutics designed to improve the lives of patients. | |
| Onxeos leading orphan oncology products at the advanced development stage are: Livatag® (Doxorubicin Transdrug): Phase III in hepatocellular carcinoma Beleodaq® (belinostat): Registered in the US in 2nd-line treatment of peripheral T-cell lymphoma Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive final results |
|
| www.onxeo.com | |
| ONXEO:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 5 fois.